Delivering Anti-Infectives

to Patients in Need​

AiCuris is an international clinical-stage biopharmaceutical company, dedicated to the development of novel, therapeutic candidates for the prevention and treatment of severe and potentially life-threatening infectious diseases in immunocompromised patients.
The Company is focused on advancing its highly differentiated product portfolio, leveraging its research and clinical development expertise to bring game-changing, high growth potential product candidates to the market and thereby to vulnerable patients with a high need for anti-infectives treatment options.

  • Demonstrated ability in delivering novel treatment options:
    PREVYMIS® (letermovir), the Company’s first-in-class antiviral agent for prophylactic use in allogeneic hematopoietic stem cell (HSC) and kidney transplant patients, prevents life-threatening cytomegalovirus (CMV) reactivation, is marketed by MSD (tradename of Merck & Co., Inc.) and generates increasing revenues.
  • Candidate with fast track to market:
    Pritelivir, a proprietary product candidate for the treatment of acyclovir resistant herpes simplex virus (HSV) infections in immunocompromised patients is currently in phase 3 development and obtained FDA breakthrough designation. Launch preparations have been initiated at AiCuris.
  • Innovative pipeline of anti-infectives:
    The anti-sense oligonucleotide (ASO) AIC468 aims to prevent active infection of BK virus (BKV) in kidney transplanted patients and is expected to enter clinical testing early next year. Preclinical programs targeting Adenovirus infections are positioned to aim to treat transplant patients, as well as ocular infections in the general population.

With a solid financial position and highly experienced management team, AiCuris is on its way to becoming a fully integrated biopharmaceutical company covering the entire value chain from research through clinical development to commercialization.

Latest News


AiCuris´ AiCubator Program Opens New Application Round for Innovative Projects with Focus on Treatment Options for Viral Infections in Immunocompromised Patients

Young start-ups and academic teams can apply to the AiCubator program starting from October 1st to December 31st, 2023.

Read more


AiCuris Received €30 Million Milestone Payment from Partner MSD Following U.S. FDA Approval of PREVYMIS® in Second Indication

PREVYMIS® now approved for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk

Read more


AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives Treatments for Immunocompromised Patients

Company will advance its highly differentiated product portfolio, including a proprietary phase 3 candidate with fast track to market.

Read more


STI & HIV 2023 World Congress 2023, 24-27 July in Chicago, USA

Meet our Head of Research, Alexander Birkmann, at his talk about Pritelivir for the treatment of resistant HSV infections in immunocompromised patients.

Read more